ClinConnect ClinConnect Logo
Search / Trial NCT04849559

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Launched by VANDA PHARMACEUTICALS · Apr 13, 2021

Trial Information

Current as of July 23, 2025

Completed

Keywords

Tradipitant Nk 1 Antagonist Neurokinin 1 Receptor

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Able to provide written consent
  • Body Mass Index (BMI) of 18-35 kg/m2
  • No medical problems or chronic diseases
  • Exclusion Criteria:
  • Diagnosis of gastrointestinal diseases
  • Structural or metabolic diseases that affect the GI system
  • A positive test for drugs of abuse at screening

About Vanda Pharmaceuticals

Vanda Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with unmet medical needs, particularly in the fields of psychiatry and sleep disorders. With a strong focus on precision medicine, Vanda leverages cutting-edge research and clinical trial methodologies to advance novel treatments that improve patient outcomes. The company's commitment to scientific excellence and patient-centric approaches positions it as a leader in delivering transformative healthcare solutions. Through its robust pipeline and strategic partnerships, Vanda aims to enhance the quality of life for individuals affected by complex medical conditions.

Locations

Rochester, Minnesota, United States

Patients applied

0 patients applied

Trial Officials

Vanda Pharmaceuticals

Study Director

Vanda Pharmaceuticals

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials